Sandra Swain, M.D.
Board Member
Immunome Inc. (IMNM)Equibles does not estimate personal net worth.
Get an email with a short summary when Immunome Inc. publishes a filing, an earnings call transcript or a press release.
Get IMNM alertsAbout Sandra Swain, M.D.
Sandra Swain, M.D. is recorded as Board Member at Immunome Inc. (IMNM) since April 25, 2024. Immunome Inc. reported in an 8-K filed April 25, 2024 that Sandra Swain, M.D. was appointed Class III director, effective April 25, 2024. Immunome Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Immunome Inc. includes Clay B. Siegall, Ph.D. (CEO), Clay Siegall (CEO), Corleen Roche (CFO) and 7 others.
“Effective April 25, 2024 (the "Appointment Date"), the Board of Directors (the "Board") of Immunome, Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Sandra Swain, M.D. as a Class III director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders.”
Affiliation history
-
Current
2024-04-25–present
-
Immunome Inc. (IMNM)
SEC 8-K
Current2024-04-25–present
Company network
Leadership on record at Immunome Inc.
- Clay B. Siegall, Ph.D. CEO
- Clay Siegall CEO
- Corleen Roche CFO
- Diane Marcou CFO
- Max Rosett CFO
- Matthew K. Robinson CTO
- Sandra Stoneman General Counsel
- Bob Lapetina Chief Accounting Officer
- Carol Schafer Board Member
- Franklyn G. Prendergast, M.D., Ph.D. Board Member